For a quarter century, Drug Development & Delivery has connected innovators, scientists, and industry leaders while spotlighting the technologies and ideas shaping the future of the industry. We celebrate 25 years of advancing the conversation!
In this case study, OSDPredict™ narrowed formulation options early, focusing development on the most viable strategies which reduced experimental burden and conserved valuable materials.
As small-molecule manufacturing becomes increasingly fragmented across regions, specialist facilities, and CDMOs, every product handoff introduces new opportunities for delay and variability. A strategic bulk secondary packaging approach can help standardize product handling, improve operational control, and strengthen resilience across complex pharmaceutical supply chains.
Dr. Shaukat Ali and Dr. Jim Huang shed light on the challenges and opportunities to improve solubility and enhance oral bioavailability of molecules in nanocrystals or crystalline suspensions.
Ben Hohl, says while imatinib and other TKIs have undoubtedly positively impacted the lives of many people living with CML, thousands of patients are still looking for drugs that provide better efficacy, tolerability, and convenience.
Dr. Mike Ulman says an important part of combination product development is compiling the regulatory submission. Without approval from regulatory bodies, products do not make it into regulated markets.
Matthew Kihara explains how silicone lends itself to optimization, customization, and therapeutic performance, and that modifying silicone chemistry presents an opportunity to optimize drug release behavior and system performance.
Robin Cohen says that novel vaccine technology does not relate simply to the antigen, but also to method of administration and route of delivery, stressing that removing needle, syringe, and refrigerator are a step toward better vaccination programs.
Woodstock Sterile Solutions is a global provider of best-in-class sterile development and manufacturing solutions – with a decades-long track record of helping healthcare companies advance molecules through clinical development into full-scale commercial production.
Throughout our 50-year history, Woodstock has been a leader in developing and deploying advanced aseptic blow-fill-seal delivery products.
We recently completed the expansion of our QC analytical laboratory, doubling the size of our previous space, and building on to our analytical expertise. We have enhanced our formulation and method development capabilities to offer fully integrated drug development and manufacturing services. We have continued to expand our blow-fill-seal capabilities. Working extensively with customers in the respiratory and ophthalmic markets for years, our BFS packaging offers viable solutions for healthcare companies in the diagnostics market as it helps to minimize the risk of human contamination, allows for precise filling and can be easily customized to meet specific needs for diagnostics customers.
Poor aqueous solubility is a key barrier for a growing share of new drug candidates, limiting their bioavailability and development potential. Evonik’s AEROPERL® 300 Pharma excipient helps formulators improve the solubility and bioavailability of poorly water-soluble APIs. Join presenter Carolina Mathias, Senior Applied Technical Manager at Evonik Smart Effects, on Thursday, November 26 at 9:00 a.m. CET for first-hand formulation guidance.
DRUG DEVELOPMENT DIRECT RESOURCES
Upcoming eNewsletter Features:
October 28 – Formulation Development
November 4 – Drug Delivery
November 11 – Parenteral Contract Manufacturing
November 18 – Controlled Release